55 reports

Global Non-insulin Diabetes Therapeutics Market 2021-2025 The analyst has been monitoring the non-insulin diabetes therapeutics market and it is poised to grow by $ 22.95 billion during 2021-2025, progressing at a CAGR of over 10% during the forecast period. Our report on non-insulin diabetes therapeutics market provides...

  • Diabetes
  • World
  • Diabetes Prevalence

Gliptins Sodium-Glucose Co-Transporter ## Inhibitor

  • Antidiabetics
  • World
  • APAC
  • North America
  • Europe
  • Health Expenditure
  • Diabetes Prevalence

Canada Diabetes Care Insulin Biguanide Gliptins Diabetes Hospital

  • Insulin
  • Insulin Delivery
  • Diabetes Care
  • Diabetes Monitoring
  • Canada
  • Diabetes Prevalence
  • Drug Approval

Efficacy and Tolerability of DPP## Inhibitor, Teneligliptin, on Autonomic and Peripheral Neuropathy in Type ## Diabetes: An Open Label, Pilot Study

  • Clinical Trial
  • World
  • G7
  • APAC

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Antidiabetics
  • Diabetes
  • Insulin
  • Biguanide
  • Alpha-Glucosidase Inhibitor
  • Packaging
  • World
  • Diabetes Medicine Sales

Effect of DPP## Inhibitor or Alpha-glucosidase Inhibitor on Postprandial Lipemia and Endothelial Dysfunction

  • Clinical Trial
  • Europe
  • G7
  • APAC

Clinical Trial Therapy Gliptins

  • Clinical Trial
  • World
  • G7
  • APAC

Type ## Diabetes Clinical Trial Sodium-Glucose Co-Transporter ## Inhibitor Hospital Gliptins

  • Clinical Trial
  • APAC
  • G7
  • Stem Cell Transplantation

World Japan Gliptins Type ## Diabetes Therapy

  • Type 2 Diabetes
  • World
  • Drug Approval
  • Dropout Rate

According to a research study published by researchers at the Sunnybrook Research Institute and the University of Toronto in Alzheimer's & Dementia: The Journal of the Alzheimer's Association (July 2020), it was found that an anti-diabetic drug, dipeptidyl peptidase-## (DPP##) inhibitor, may have the potential to slow memory loss in patients with Alzheimer's disease.

  • Dementia
  • Therapy
  • Pharmaceutical
  • APAC
  • Europe
  • South America
  • Dementia Prevalence
  • Elderly Population

World Pharmaceutical Research And Development Molecular Biology Genomics Cell Therapy Gliptins

  • Genomics
  • Research And Development
  • World
  • APAC
  • Nanotechnology Revenue
  • Number Of Enterprises

A Dipeptidyl Peptidase ## (DPP-##) Inhibitor in Type ## Diabetes DPP## inhibitors in Type ## Diabetes GDCT## NCT##, 2012DM##;EudraCT-2012-##-##;UKCRN##;2012-##-##;T##/## Metabolic Disorders Hypoglycemia, Type ## Diabetes (Juvenile Diabetes) Completed Phase III Interventional saxagliptin University of Dundee;NHS Tayside Tenovus Scotland ## Sep 2012 ## Sep 2012 ## Apr 2014 ## Apr 2014 ##

  • Clinical Trial
  • G7
  • APAC
  • Caesarean Section Performed
  • Diagnostic Imaging Density

Metabolex CymaBay Therapeutics Sanofi World Type ## Diabetes Drug Development Therapy Hospital Insulin Research And Development Gliptins Diabetes

  • Type 2 Diabetes
  • Pharmaceutical
  • World
  • Japan
  • Smoking Prevalence
  • LED Export

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction

  • Neurological Disorder
  • World
  • Pharmaceutical Registrations
  • Biologics Sales

This study covers the world outlook for diabetes drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative...

  • Diabetes
  • World
  • Gross Domestic Product
  • Disposable Income

Japan United States European Union Therapy Type ## Diabetes Gliptins

  • Clinical Trial
  • Type 2 Diabetes
  • Japan
  • India
  • China
  • United States
  • Drug Approval
  • Prescription Drug Sales

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Drug Development
  • World
  • Hospital Admission
  • Pharmaceutical Registrations

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Cardiovascular Disease
  • World
  • Surgical Procedures Performed
  • Mortality Rate

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Chronic Disease
  • Genitourinary System Disease
  • World
  • United States
  • North America
  • Drug Approval
  • Pharmaceutical Registrations

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Hypertension
  • South Africa
  • Drug Approval
  • Cause-Specific Mortality Rate

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Neurological Disorder
  • World
  • South Africa
  • Number Of R&D Personnel
  • Biologics Production

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Neurological Disorder
  • World
  • Hospital Discharge
  • Pharmaceutical Registrations

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Genitourinary System Disease
  • World
  • United States
  • Pharmaceutical Registrations
  • Hospital Occupancy Rate

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Hypertension
  • World
  • United States
  • North America
  • Drug Approval
  • Pharmaceutical Registrations

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Neurological Disorder
  • Therapy
  • World
  • South Africa
  • Number Of R&D Personnel
  • Drug Approval

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Therapy
  • Pharmaceutical
  • World
  • Prescription Drug Sales
  • Hospital Admission

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Cardiovascular Disease
  • Therapy
  • World
  • Mortality Rate
  • Hospital Discharge

DPP## Inhibitors

  • Therapy
  • Clinical Trial
  • United States
  • Overweight Prevalence
  • Sugar Consumption

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Cancer
  • Therapy
  • Drug Development
  • Oncology
  • Oncology
  • Biopharmaceutical
  • World
  • Pharmaceutical Registrations
  • Drug Approval

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Drug Development
  • Therapy
  • Pharmaceutical
  • World
  • Prescription Drug Sales
  • Hospital Admission